- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01921322
Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy
Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy for Hospitalized Patients in China With Type 2 Diabetes; Time to Target
Studieoversigt
Detaljeret beskrivelse
Primary objective:
To compare the length of time to achieve target glucose range using Self-Monitoring Blood Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus MDI
Secondary Objectives:
To compare glycemic variability (using CGM as reference method) with the 722 Paradigm Real-Time insulin pump versus MDI
This is a prospective, randomized (open label), multi-center study. The clinical study staff will conduct screening tests according to inclusion/exclusion criteria in order to verify the subject's eligibility for the study.
Inpatient Period A patient is admitted into hospital for treatment of diabetes
Randomization
Subjects are randomized (at a 1:1 ratio) to group A or B in the study database. A total of 80 subjects will be randomized into 2 study groups:
- Group A will wear 722 Paradigm Real-Time System (treated with 24h per day insulin infusion)
- Group B will be on MDI and wear the CGMS-Gold (treated with 4 insulin injections).
It is anticipated that the total duration for the study will be within one year from site initiation to finalization of all data entry and monitoring.
Each subject will participate in the study approximately 2 weeks.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Beijing, Kina
- Chinese PLA General Hospital
-
-
Jilin
-
Changchun, Jilin, Kina
- The Second Hospital of Jilin University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Subject is 18 to 65 years old at time of screening
- A clinical diagnosis of type 2 diabetes > 6 months prior to the screening as determined by the Investigator,
- Treating with insulin at least one injection per day prior to participate in the study
- Glycosylated hemoglobin (A1C) > 8% at screening
- Subject needs to be hospitalized to receive treatment for glucose management according to Endocrinologists' discretion
- Subject is willing to follow protocol and underdo all study procedures
- Subject is willing and able to provide informed written consent personally or by legal proxy
Exclusion Criteria:
- Subject has known hypersensitivity to insulin or insulin infusion set
- Subject has been treated with drugs with a known effect on BG within 8 weeks before enrollment other than diabetes medications such as insulin or oral agents.
- random blood glucose is above 33 mmol/L
- Subject is currently using real time CGM therapy prior to screening
- Subject is currently using insulin pump therapy prior to screening
- Female subject who is pregnant, or plans to become pregnant during the course of the study
- Patients who are critically ill that must go to intensive critical care unit per Investigator discretion
Subject has any systemic disease or medical condition found on the screening tests that may interfere with the safety of the patient and efficacy of the study treatment, in the opinion of the Investigator, may preclude him/her from participating in the study. The following includes, but not limited to, those conditions:
- Female subject has a positive serum pregnancy screening test
- Subject has visually impaired or disability limits the use of RT-CGM.
- Subject has any unresolved adverse skin condition in the area of sensor placement or device replacement (e.g., psoriasis, rash, Staphylococcus infection)
- Subject has disease with a known effect on BG such as Active Graves' disease
- Subject has a history of alcohol abuse
- Any other condition, which may not be suitable for the study at physician's discretion.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Pump
Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
|
722 Paradigm Real-Time System
|
|
Aktiv komparator: MDI
Multiple daily insulin injections used for treatment
|
Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to Target
Tidsramme: Up to 14 days in hospital
|
length of time to achieve target glucose range using Self-Monitoring Blood Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus Multiple Daily Injection
|
Up to 14 days in hospital
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Glycemic Variability
Tidsramme: Up to 14 days in hospital
|
Glycemic variability (mean amplitude glycemic excursion) using CGM as reference method
|
Up to 14 days in hospital
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CEP270
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 2 diabetes
-
Jin-Hee AhnAsan Medical CenterUkendtHER-2-genamplifikation | HER-2 Protein Overekspression
-
The University of Tennessee, KnoxvilleAfsluttetMatematiklærere (2-8 klassetrin) | Matematikstuderende (2-8 klassetrin)Forenede Stater
-
Instituto Nacional de Ciencias Medicas y Nutricion...Aktiv, ikke rekrutterende
-
Endogenex, Inc.Ikke rekrutterer endnuDiabetes mellitus, type 2 | Diabetes | Type 2 diabetes | Type 2 diabetes mellitus (T2DM) | Type 2 Diabetes
-
Tianjin Medical University Second HospitalJiangsu HengRui Medicine Co., Ltd.UkendtSolid tumor | HER-2-genamplifikation | HER2 genmutation | HER-2 Protein OverekspressionKina
-
PowderMedAfsluttet
-
Embecta Corp.Jaeb Center for Health ResearchTrukket tilbageType 2 diabetes | Type 2 diabetes mellitus (T2DM) | T2DM (Type 2 Diabetes Mellitus) | T2D | T2DM | Type 2 DM | T2DM med utilstrækkelig glykæmisk kontrolForenede Stater
-
University of North Carolina, Chapel HillAmerican Heart AssociationRekrutteringType 2 diabetes | Ernæring | Diabetes type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes uddannelseForenede Stater
-
Kaiser PermanenteThe Permanente Medical GroupTilmelding efter invitationType 2 diabetes | Type 2 diabetes mellitus (T2DM) | Type 2-diabetes (T2D)Forenede Stater
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi... og andre samarbejdspartnereIkke rekrutterer endnuType 2 diabetes | Diabetes mellitus type 2Tyrkiet (Türkiye)
Kliniske forsøg med Pump
-
The University of Texas Health Science Center,...AfsluttetHjertefejl | LVADForenede Stater
-
Bozok UniversityAfsluttetMyokardieinfarkt | Oxidativt stress | Cerebral iltningKalkun
-
Assiut UniversityRekrutteringCAD - KoronararteriesygdomEgypten
-
Medtronic ItaliaAfsluttetKoronararteriesygdomSchweiz, Italien
-
St. Petersburg State Pavlov Medical UniversityAfsluttetKoronararteriesygdom | CABG | Iskæmisk hjertesygdom | Iskæmisk reperfusionsskadeDen Russiske Føderation
-
University of PittsburghAfsluttet
-
NYU Langone HealthTrukket tilbage
-
KORU Medical Systems, Inc.Ikke rekrutterer endnuPrimære immundefekter (PID) | Sekundære immundefekter (SID)Det Forenede Kongerige
-
University of AlexandriaIkke rekrutterer endnuDelirium | Åben hjertekirurgiEgypten
-
Suzhou Hechun Medical Technology Co., Ltd.AfsluttetAt evaluere effektiviteten og sikkerheden af insulin-patch-pumpesystemet hos patienter med diabetes.Type 1 diabetes | Type 2 diabetesKina